NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte Inc., a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today that results from the Phase 2b clinical trial of jCell in retinitis pigmentosa will be presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting, held July 24-26, 2020.
jCell is a first-in-class investigational treatment for retinitis pigmentosa which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
“We are excited and privileged to have the opportunity to present for the first time, our Phase 2b data evaluating our investigational therapy jCell in retinitis pigmentosa at ASRS,” said Paul Bresge, Chief Executive Officer, jCyte, Inc. “This year’s virtual ASRS scientific program provides a timely opportunity to share key clinical updates with the medical community.”
Details of the virtual ASRS 2020 scientific presentation:
Oral Presentation: Intravitreal injection of allogeneic human retinal progenitor cells (jCell) for treatment of retinitis pigmentosa: Results from the Phase 2b trial
Presenter: Anthony Joseph, M.D., Ophthalmic Consultants of Boston
Session Title: Hereditary Retinal Diseases & Genetics Symposium
About jCyte, Inc.
jCyte, Inc. is a clinical-stage biotech company focused on developing jCell therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. jCell is a first-in-class investigational treatment for retinitis pigmentosa, an inherited retinal disease. The treatment is minimally-invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP. The company is pioneering a new era of regenerative therapies to treat patients with unmet medical need. For more information, visit www.jcyte.com